New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven no...
Spremljeno u:
| Glavni autori: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2020-06-01
|
| Serija: | Cells |
| Teme: | |
| Online pristup: | https://www.mdpi.com/2073-4409/9/6/1522 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|